Advancing Innovation
Since 2013
Founded in 2013, YD Bio is dedicated to developing advanced detection and therapeutic technologies that transform healthcare. Our work spans non-invasive early cancer detection, regenerative approaches in ophthalmology and exosome science. All driven by a commitment to address urgent health challenges and improve patient outcomes worldwide.
Company History
A decade of scientific innovation, global partnerships, and strategic expansion into breakthrough therapies.
2013 - 2015
Foundation & Global Partnerships
Pharmacy & Supplement Origins
Established to manage clinical trial drugs, and develop targeted nutritional supplements.
Global Expansion
Became a clinical trial supplier to leading pharmaceutical companies.
2024 - Present
Breakthroughs in Exosome Innovation
Exosome R&D Partnership
Partnered with 3D Global Biotech Inc. to pioneer stem cell-derived exosome solutions for eyecare.
2024 - Present
New Platforms & Market Entry
Cancer Detection Platform
Partnered with EG Biomed to launch a U.S.-based CAP Accredited and CLIA Certified lab focused on DNA methylation analysis, accelerating our entry into early cancer detection.
A Team of Innovators
and Builders
Our leadership team brings together decades of expertise in biotechnology, clinical research, operations, and global partnerships. United by a shared mission, we combine scientific rigor with entrepreneurial drive to bring transformative biomedicine to patients worldwide.
Global Reach
Founded in Taiwan.
With office and partner lab in North America.
Listed on Nasdaq.
Positioned to advance global health.
